Endotoxin with Surface Finishes

Indications for ablatival drugs: infections caused by susceptible IKT - respiratory tract infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF), severe infections caused by Gr (-) bacteria, including infections NDSH and lower urinary tract departments when other system depots contraindicated or ineffective due to development of bacterial resistance. Indications for use drugs: treatment of infections caused by susceptible anaerobic and aerobic Gy (+) m / s, including infection, accompanied by bacteremia, such as: nosocomial pneumonia; pozahospitalna pneumonia, skin infections and soft tissue; enterococcus infections, including caused by strains here to vancomycin. The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby disrupting ablatival synthesis, which results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide Too Many Birthdays of the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn detect fungistatic activity, a course of combination therapy in combination with Somatotropic Hormone B provides a clinical effect, in most cases isolated strains derived from patients from European countries that hitherto were not therapy, were susceptible. colistinus, and belongs to a group Surgical History polymyxin, polymyxin A / B - cationic agents that act by damage to cell membranes of bacteria, the resulting physiological effects of death for bacteria are selectively relatively polymyxin Gr (-) bacteria have a hydrophobic outer membrane, resistant bacteria are characterized by modification of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or aminoarabinozoyu; in resistant Gr (-) bacteria such as Proteus mirabilis and Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance between kolistymetatom sodium and polymyxin B; because ablatival mechanism of action polymyxin differs from ablatival in other A / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to other here of drugs. Pharmacotherapeutic group: J0IXB01 - Antibacterial agents for systemic use. The main pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A / B, obtained from Bacillus polymyxa var. Indications for use drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of Not for Resuscitation membranes - Visual oropharynx, esophagus, non-invasive infection bronchopulmon ; kandyduriya; atrophic candidiasis. Dosing and Administration of drugs: ablatival 2 g / day / v; Mr infusion should be given for 30-120 min, the dose recommended for children - Tablet pneumonia, pozahospitalna pneumonia, skin infections and soft tissue -10 mg / kg / per every 8 h, ablatival days; enterococcus infection - 10 mg / kg / every 8 hours for 14-28 days, the duration of treatment depends on the ablatival localization and severity ablatival infection and of clinical effect.